{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/tamoxifen-managing-adverse-effects/management/tamoxifen-prescribing-information/","result":{"pageContext":{"chapter":{"id":"fc761c4a-bd2a-5463-96c8-861d67a66e30","slug":"tamoxifen-prescribing-information","fullItemName":"Scenario: Tamoxifen - prescribing information","depth":2,"htmlHeader":"<!-- begin field 564207d5-2067-4240-9f36-f6958efff173 --><h2>Scenario: Tamoxifen - prescribing information</h2><!-- end field 564207d5-2067-4240-9f36-f6958efff173 -->","summary":"Covers the prescribing information on tamoxifen and the primary care management of women taking tamoxifen.","htmlStringContent":"<!-- begin item 780fbda6-ff5f-413d-8344-8437780d95a5 --><!-- begin field 11fa8681-fa17-47cc-925c-acbc015abb73 --><p>From age 18 years onwards (Female).</p><!-- end field 11fa8681-fa17-47cc-925c-acbc015abb73 --><!-- end item 780fbda6-ff5f-413d-8344-8437780d95a5 -->","topic":{"id":"843d50d1-29e0-5a25-b29d-4d009d4ca56b","topicId":"3c8ceccf-c939-4885-bf43-dff38de8f940","topicName":"Tamoxifen - managing adverse effects","slug":"tamoxifen-managing-adverse-effects","lastRevised":"Last revised in November 2019","chapters":[{"id":"68b30489-1c21-5691-aa91-d98c85819055","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3902ae23-4436-5f34-954f-61ee513623ad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9c316fc9-3054-50cd-8e92-91608fd623e3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"822375d2-f573-54dc-9af4-4cafe8094b70","slug":"changes","fullItemName":"Changes"},{"id":"4fc88cec-4de4-5284-976a-8ff9c926937b","slug":"update","fullItemName":"Update"}]},{"id":"3254e7b2-0406-5c0f-bd0a-d382915875ec","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"853ae85c-163b-5ccf-a644-b072b18b9fca","slug":"goals","fullItemName":"Goals"},{"id":"c3b62b71-183a-5bee-bd03-125e3b658e3c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bae49ff-a702-5f72-b2d0-f46009108792","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"dbdc028f-d934-59f6-91ca-bf671c6ed1bd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3b6ca9fb-1d57-5cbb-9532-96c1bff9189d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ca455d2-3037-5131-bb24-2196750b0f52","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"204b504a-d22b-5a27-a20f-f08f20c3591b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69c80182-34aa-574b-8416-bc35ff6b2570","slug":"definition","fullItemName":"Definition"}]},{"id":"1f50f511-890e-545d-8d87-c607a1a4d1e2","fullItemName":"Management","slug":"management","subChapters":[{"id":"fc761c4a-bd2a-5463-96c8-861d67a66e30","slug":"tamoxifen-prescribing-information","fullItemName":"Scenario: Tamoxifen - prescribing information"}]},{"id":"f7ed77db-551a-5fd6-92d5-f93f53a97371","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"da6173b5-10a1-58a6-9931-e08d1f99d6c0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ae24edbd-49ce-530e-9e4b-4367a855974e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4fa9ad0b-2994-5c86-99d2-265267b32373","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bbed3b56-4479-5b7a-a72a-79307a374780","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebc820e0-9d21-571c-b402-0ca097dbf174","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2cc02a-ab60-597e-a108-ae6b27aafd5d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"41fcafe7-39c4-51a2-b67a-c091704fdf89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1f50f511-890e-545d-8d87-c607a1a4d1e2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"924589c0-c18e-5c94-b822-70b40490882d","slug":"initiation","fullItemName":"Initiation","depth":3,"htmlHeader":"<!-- begin field f4ad070a-fd3c-42b4-b397-43d05482bac5 --><h3>How is tamoxifen initiated?</h3><!-- end field f4ad070a-fd3c-42b4-b397-43d05482bac5 -->","summary":null,"htmlStringContent":"<!-- begin item 5c96a7a7-c3a0-4f9f-ac80-b0cc39816fc2 --><!-- begin field c7f7db99-7e94-4c05-8e55-101bd078067b --><ul><li><strong>Tamoxifen is<em> </em>always initiated in secondary care by a speciali</strong><strong>st. However, treatment may be continued and monitored in primary care.</strong><ul><li><strong>For the treatment of breast cancer</strong><strong>, </strong>the recommended dose is normally 20 mg daily.<ul><li>No additional benefit, in terms of delayed recurrence or improved survival, has been demonstrated with higher doses.</li><li>Substantive evidence supporting the use of treatment with 30–40 mg per day is not available, although these doses have been used in some women with advanced disease.</li></ul></li><li><strong>For the treatment of anovulatory infertility:</strong><ul><li>In women who are menstruating regularly but with anovular cycles, the recommended dose is initially 20 mg taken on days 2, 3, 4, and 5 of the menstrual cycle. If unsatisfactory basal temperature records or poor pre-ovulatory cervical mucus indicate that this initial course of treatment has been unsuccessful, further courses may be given during subsequent menstrual periods, increasing the dose to 40 mg and then 80 mg daily.</li><li>In women who are not menstruating regularly, the initial course can be started on any day. If no signs of ovulation are demonstrable, then a subsequent course of treatment may start 45 days later, with dosage increased as above, or on day 2 of the cycle if menstruation occurs.</li></ul></li><li><strong>For the primary prevention of breast cancer in women at moderate to high risk</strong><strong><strong>,</strong> </strong>the recommended dose is 20 mg daily for 5 years.<ul><li>There are insufficient data to support a higher dose or longer period of use.</li><li>The use of tamoxifen should be as part of a program including regular breast surveillance tailored to the individual woman, taking into account her risk of breast cancer.</li></ul></li></ul></li></ul><!-- end field c7f7db99-7e94-4c05-8e55-101bd078067b --><!-- end item 5c96a7a7-c3a0-4f9f-ac80-b0cc39816fc2 -->","subChapters":[{"id":"13338290-e0e0-5fe2-a57b-272fe45f373a","slug":"basis-for-recommendation-5ea","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 791a137b-313a-4500-a5ca-78b4b6f6a42e --><h4>Basis for recommendation</h4><!-- end field 791a137b-313a-4500-a5ca-78b4b6f6a42e -->","summary":null,"htmlStringContent":"<!-- begin item 5ea2ffe8-c92a-4531-9970-db8c11f7f2a8 --><!-- begin field f2dbf00b-98f8-450a-a5b3-b15f93e4f16d --><p>This information is taken from the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Joint Formulary Committee, 2019</a>].</p><!-- end field f2dbf00b-98f8-450a-a5b3-b15f93e4f16d --><!-- end item 5ea2ffe8-c92a-4531-9970-db8c11f7f2a8 -->","subChapters":[]}]},{"id":"a3e941f2-372b-56c1-ae2e-42e840fecb76","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f82680d1-28b6-4e02-b494-2124f298c640 --><h3>What are the contraindications and cautions for tamoxifen?</h3><!-- end field f82680d1-28b6-4e02-b494-2124f298c640 -->","summary":null,"htmlStringContent":"<!-- begin item d7bdb3ff-e767-4c84-b3c9-dc5a216a8743 --><!-- begin field 458f4f52-8fc9-46fa-82a0-f70b236e6fd7 --><ul><li><strong>Contraindications</strong><ul><li>Unless being used in the treatment of female infertility, effective contraception must be used during treatment and for 2 months after stopping. Pregnancy — there have been few reports of spontaneous abortions, birth defects, and fetal deaths following the use of tamoxifen during pregnancy, although no causal relationship has been established. The manufacturer advises that it should not be used during pregnancy.</li><li>Breastfeeding — it is not known if tamoxifen is excreted in human milk. The manufacturer states that it is not recommended during breastfeeding. </li><li>Thrombotic disease — there is a small increased risk of thrombotic disease associated with tamoxifen treatment. It is, therefore, contraindicated in:<ul><li>Treatment of infertility in women with a personal or family history of idiopathic venous thromboembolism (VTE) or a genetic predisposition to thromboembolism.</li><li>Primary prevention of breast cancer in women with a history of deep vein thrombosis or pulmonary embolism.</li></ul></li></ul></li><li><strong>Cautions</strong><ul><li>Thrombotic disease — there is a small increased risk of thrombotic disease associated with tamoxifen treatment. It should, therefore, be used with caution for:<ul><li>Treatment of breast cancer in women with a personal or family history of idiopathic VTE or a genetic predisposition to thromboembolism.</li></ul></li><li>Acute porphyria — may be aggravated by tamoxifen.</li><li>Premenopausal women<strong> </strong>— tamoxifen has been associated with reduced bone density in premenopausal women, although it is not known whether this may result in an increased risk of fracture.<ul><li>Premenopausal women taking tamoxifen should be advised regarding measures to maintain bone health.</li><li>Tamoxifen does not adversely affect bone mineral density in postmenopausal women.</li></ul></li></ul></li><li><strong>The possibility of <a class=\"topic-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/management/tamoxifen-prescribing-information/#drug-interactions\">drug interactions</a> with tamoxifen should also be considered.</strong></li></ul><!-- end field 458f4f52-8fc9-46fa-82a0-f70b236e6fd7 --><!-- end item d7bdb3ff-e767-4c84-b3c9-dc5a216a8743 -->","subChapters":[{"id":"7f9223e4-67f8-5c8e-b12d-2f02d0e742dc","slug":"basis-for-recommendation-054","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fa77102a-f4c2-428e-b735-da18018a6bc5 --><h4>Basis for recommendation</h4><!-- end field fa77102a-f4c2-428e-b735-da18018a6bc5 -->","summary":null,"htmlStringContent":"<!-- begin item 0548d8e4-74e9-4009-bd71-4448715bbd3a --><!-- begin field ab0253cd-b5cd-494c-9b1a-f21dcd15d1db --><p>This information is largely taken from the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Joint Formulary Committee, 2019</a>].</p><h5>Thrombotic disease</h5><ul><li>Due to the small increased risk of thrombotic disease associated with tamoxifen treatment, it is contraindicated for the:<ul><li>Treatment of anovulatory infertility in women with known personal or family history of idiopathic venous thromboembolism (VTE) or a genetic predisposition to thromboembolism.</li><li>Prevention<em> </em>of breast cancer in women with known personal or family history of idiopathic VTE or a genetic predisposition to thromboembolism.</li></ul></li><li>However, for the treatment<em> </em>of breast cancer, it is thought that the overall benefits from tamoxifen clearly outweigh this risk; therefore, it can be used with caution. </li></ul><h5>Bone mineral density</h5><ul><li>This information is also based on the National Institute for Health and Care Excellence (NICE) guideline <em>Early and locally advanced breast cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">NICE, 2018</a>] and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Heery, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Ramchand, 2019</a>].<ul><li>Tamoxifen is a <a class=\"topic-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/background-information/definition/\">selective oestrogen receptor modulator</a> (SERM) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Heery, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Ramchand, 2019</a>].</li><li>In contrast to its action as a pure oestrogen receptor antagonist in breast tissue, tamoxifen acts as a partial oestrogen receptor agonist in bones and its actions depend on menopausal status (as tamoxifen is less potent than native oestradiol) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Ramchand, 2019</a>]:<ul><li>In premenopausal women, in whom circulating oestradiol concentrations are high, tamoxifen acts as a partial antagonist, competing with oestradiol for the oestrogen receptor-binding sites and causing bone loss. </li><li>In postmenopausal women, where endogenous oestradiol concentrations are low, tamoxifen acts as a partial agonist, preventing bone loss and reducing fracture risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Ramchand, 2019</a>].</li></ul></li><li>NICE states that the benefits and risks of tamoxifen treatment, including possible bone density loss in premenopausal women should be discussed with the woman [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">NICE, 2018</a>]. </li><li>The manufacturer states that the use of tamoxifen for reduction of breast cancer risk has been associated with reduced bone density in premenopausal women, and advises that premenopausal women taking tamoxifen for this reason should be advised regarding measures to maintain bone health [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>]. </li></ul></li></ul><!-- end field ab0253cd-b5cd-494c-9b1a-f21dcd15d1db --><!-- end item 0548d8e4-74e9-4009-bd71-4448715bbd3a -->","subChapters":[]}]},{"id":"f569d99c-6e78-5513-90c6-53d891f3c9e4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 232bc037-c1d6-416b-92b7-3f6433a3da2d --><h3>What are the adverse effects of tamoxifen?</h3><!-- end field 232bc037-c1d6-416b-92b7-3f6433a3da2d -->","summary":null,"htmlStringContent":"<!-- begin item ee8a8d63-fb43-4d46-bddf-1fcecb163e21 --><!-- begin field 49ab7d2b-8420-4571-904a-19f6d4e1e4c0 --><ul><li><strong>The most common adverse effects of tamoxifen are </strong>hot flushes (reported in about 50% of women), nausea, fluid retention, vaginal bleeding, vaginal discharge, fatigue, and skin rash.</li><li><strong>Other common adverse effects include:</strong><ul><li>Blood and lymphatic system disorders — anaemia.</li><li>Eye disorders — cataracts and retinopathy.</li><li>Gastrointestinal disorders — vomiting, diarrhoea, and constipation.</li><li>Hepatobiliary disorders — changes in liver enzymes and fatty liver.</li><li>Immune system disorders — hypersensitivity reactions.</li><li>Musculoskeletal and connective tissue disorders — muscle pain and leg cramps.</li><li>Neoplasms — uterine fibroids.</li><li>Nervous system disorders — ischaemic cerebrovascular events, headache, light headedness, dizziness, and sensory disturbances (including paraesthesia and distortion of the sense of taste).</li><li>Reproductive system disorders — pruritus vulvae and endometrial changes (including hyperplasia and polyps).</li><li>Skin and subcutaneous tissue disorders — alopecia.</li><li>Vascular disorders — thromboembolic events (including deep vein thrombosis, microvascular thrombosis, and pulmonary embolism).</li><li>Others — elevated triglycerides.</li></ul></li><li><strong>Uncommon adverse effects include:</strong><ul><li>Blood and lymphatic system disorders — thrombocytopenia and leukopenia.</li><li>Eye disorders — visual disturbances.</li><li>Hepatobiliary disorders — cirrhosis of the liver.</li><li>Neoplasms — endometrial cancer.</li><li>Others — pancreatitis, interstitial pneumonitis, and hypercalcaemia (in women with bony metastases).</li></ul></li><li><strong>Rare adverse effects include:</strong><ul><li>Blood and lymphatic system disorders — neutropenia and agranulocytosis.</li><li>Eye disorders — corneal changes and optic neuropathy.</li><li>Hepatobiliary disorders — hepatitis, cholestasis, hepatic failure, hepatocellular injury, and hepatic necrosis.</li><li>Nervous system disorders — optic neuritis.</li><li>Neoplasms — uterine sarcoma (mostly malignant mixed Mullerian tumours) and tumour flare.</li><li>Reproductive system disorders — endometriosis, cystic ovarian swelling, and vaginal polyps.</li><li>Skin and subcutaneous tissue disorders — angioedema, Steven-Johnson syndrome, cutaneous vasculitis, bullous pemphigoid, erythema multiforme, and cutaneous lupus erythematosus (all very rare).</li><li>Others — porphyria cutanea tarda (very rare) and radiation recall (very rare).</li></ul></li></ul><!-- end field 49ab7d2b-8420-4571-904a-19f6d4e1e4c0 --><!-- end item ee8a8d63-fb43-4d46-bddf-1fcecb163e21 -->","subChapters":[{"id":"e2526bb7-76e0-5090-91f5-fe1e19cd79e9","slug":"basis-for-recommendation-6dd","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f8bb153b-afac-426d-9e2b-e5010c986f60 --><h4>Basis for recommendation</h4><!-- end field f8bb153b-afac-426d-9e2b-e5010c986f60 -->","summary":null,"htmlStringContent":"<!-- begin item 6dde4e08-80c5-40db-98e4-67350d236e21 --><!-- begin field 3b72b3fa-b2cf-47c8-8494-3e256f2689e9 --><p>This information is taken from the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Joint Formulary Committee, 2019</a>].</p><!-- end field 3b72b3fa-b2cf-47c8-8494-3e256f2689e9 --><!-- end item 6dde4e08-80c5-40db-98e4-67350d236e21 -->","subChapters":[]}]},{"id":"51ed7859-4718-595f-a000-f3556bdcebb7","slug":"managing-adverse-effects","fullItemName":"Managing adverse effects","depth":3,"htmlHeader":"<!-- begin field a16bb436-5d6c-4ea2-80cf-95433fc14f05 --><h3>How should I manage adverse effects associated with tamoxifen?</h3><!-- end field a16bb436-5d6c-4ea2-80cf-95433fc14f05 -->","summary":null,"htmlStringContent":"<!-- begin item 205bd057-e799-4a86-9084-b63e8b4321e0 --><!-- begin field 694001f2-baa8-4c36-a8db-e99649467cd1 --><ul><li><strong>If there are symptoms suggestive of a gynaecological cancer, such as abnormal vaginal bleeding or discharge: </strong><ul><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a> for management information.</li></ul></li><li><strong>If there are symptoms suggestive of thromboembolism, such as pain and swelling in the calf of one leg and sudden breathlessness: </strong><ul><li>Use the two-level DVT or PE Wells score to assess the probability of deep vein thrombosis (DVT) or pulmonary embolism (PE), and manage accordingly.</li><li>See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/deep-vein-thrombosis/\">Deep vein thrombosis</a> and <a class=\"topic-reference external-reference\" href=\"/topics/pulmonary-embolism/\">Pulmonary embolism</a> for more information.</li></ul></li><li><strong>For nausea:</strong><ul><li>Advise the woman to take tamoxifen with food or milk, or at night.</li><li>Advise that although nausea is quite common initially, it usually improves after a few weeks.</li></ul></li><li><strong>For menopausal symptoms:</strong><ul><li>Provide information on non-hormonal and non-pharmacological treatments, such as antidepressants, vaginal moisturisers and lubricants, cognitive behavioural therapy, and relaxation techniques.</li><li>See the sections on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#managing-co-morbidities\">Managing women with comorbidities</a> and <a class=\"topic-reference external-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#non-hormonal-treatments\">Managing menopausal symptoms without hormone replacement therapy</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a> for more information.</li></ul></li><li><strong>For all other <a class=\"topic-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/management/tamoxifen-prescribing-information/#adverse-effects\">adverse effects</a> of tamoxifen:</strong><ul><li>Manage in primary care (if appropriate) or refer appropriately.</li></ul></li></ul><!-- end field 694001f2-baa8-4c36-a8db-e99649467cd1 --><!-- end item 205bd057-e799-4a86-9084-b63e8b4321e0 -->","subChapters":[{"id":"7e359659-3418-5665-874a-99eaf3caed0b","slug":"basis-for-recommendation-42c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9a5218b6-f27f-46a6-b41c-2383b053dbc7 --><h4>Basis for recommendation</h4><!-- end field 9a5218b6-f27f-46a6-b41c-2383b053dbc7 -->","summary":null,"htmlStringContent":"<!-- begin item 42c54829-2bf6-4a8a-aecd-60628ecaed05 --><!-- begin field 4aa34ecb-f0ba-4029-84b6-ad3e40e57acc --><h5>Managing nausea</h5><ul><li>The recommendation to advise the woman to take tamoxifen with food or milk, or at night, is a pragmatic recommendation based on the fact that drug-induced nausea may sometimes be relieved by these measures.</li><li>This recommendation is in line with advice issued by Macmillian Cancer Support [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Macmillan Cancer Support, 2018</a>].</li></ul><h5>Managing menopausal symptoms</h5><ul><li>Hormone replacement therapy (HRT) is not recommended for managing menopausal symptoms in women taking tamoxifen because both tamoxifen and HRT can increase the risk of thromboembolism, and there is some evidence that HRT may reduce the effectiveness of tamoxifen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>].</li><li>In addition, HRT is contraindicated in women with current, past, or suspected breast cancer. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a> for more information.</li></ul><h5>Managing all other symptoms</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice.</li></ul><!-- end field 4aa34ecb-f0ba-4029-84b6-ad3e40e57acc --><!-- end item 42c54829-2bf6-4a8a-aecd-60628ecaed05 -->","subChapters":[]}]},{"id":"214e62b6-833d-5dd1-b8fb-6ab4d26e79a7","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1dab0c43-5048-4df4-b565-77d74ef31d38 --><h3>What are the key drug interactions with tamoxifen?</h3><!-- end field 1dab0c43-5048-4df4-b565-77d74ef31d38 -->","summary":null,"htmlStringContent":"<!-- begin item c7154ec2-e797-4197-8e37-c1740934066d --><!-- begin field f534649f-5340-4b42-8d2d-8118aab825bd --><ul><li><strong>Possible drug interactions with tamoxifen include:</strong><ul><li><strong>Anastrozole </strong>— the use of tamoxifen in combination with anastrozole as adjuvant therapy has not shown improved efficacy compared with tamoxifen alone. <ul><li>The manufacturer states that concurrent treatment is contraindicated.</li></ul></li><li><strong>Cytochrome P450 2D6 (CYP2D6)</strong><strong><strong> </strong>inhibitors </strong>— tamoxifen is a prodrug that is extensively metabolized to more potent active metabolites (the most significant of which is endoxifen) by the liver enzyme CYP450. Inhibition of this enzyme potentially prevents formation of the active compounds, thereby decreasing the efficacy of tamoxifen. <ul><li>Potent CYP2D6 inhibitors (such as paroxetine, fluoxetine, quinidine, cinacalcet, and bupropion) should, whenever possible, be avoided during tamoxifen treatment.</li><li>If antidepressant treatment is indicated, preference should be given to those with weak inhibitory effects on CYP2D6, such as citalopram, escitalopram, sertraline, and venlafaxine. </li></ul></li><li><strong>Hormonal contraceptives</strong> — both tamoxifen and oral contraceptives can increase the risk of thromboembolism.<ul><li>Concurrent use is not recommended.</li><li>In addition, progestogen-only contraception, combined hormonal contraception, and the levonorgestrel intrauterine system (LNG-IUS) are contraindicated in women with current breast cancer due to unacceptable health risks (UKMEC 4), and should only be used after consultation with an expert (UKMEC 3) in women with a history of breast cancer and no evidence of recurrence for 5 years. See the section on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/management/assessment-for-specific-contraceptive-methods/\">Assessment for specific contraceptive methods</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for more information.</li></ul></li><li><strong>Hormone replacement therapy (HRT) — </strong>both tamoxifen and HRT can increase the risk of thromboembolism, and there is some evidence that HRT may reduce the effectiveness of tamoxifen.<ul><li>Concurrent use is not recommended.</li><li>In addition, HRT is contraindicated in women with current, past, or suspected breast cancer. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a> for more information.</li></ul></li><li><strong>Tibolone — </strong>both tamoxifen and HRT can increase the risk of thromboembolism.<ul><li>Concurrent use is not recommended.</li><li>In addition, tibolone is contraindicated in women with known, past, or suspected breast cancer, as it may increase the risk of breast cancer recurrence. </li></ul></li><li><strong>Warfarin — </strong>tamoxifen enhances the anticoagulant effects of warfarin.<ul><li>In women receiving tamoxifen for the primary prevention of breast cancer, the use of coumarin-type anticoagulants (such as warfarin) is contraindicated.</li><li>For all other women, monitor international normalized ratio (INR) closely, and reduce the dose of warfarin if needed.</li></ul></li></ul></li><li><strong>For a complete </strong><strong>list of possible drug interactions with tamoxifen,</strong><strong> </strong>see the <a data-hyperlink-id=\"4e6664e6-0e75-404c-8a65-a98f0186e821\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"e7040e84-a7fd-4a00-8e66-a98f0186e84b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><!-- end field f534649f-5340-4b42-8d2d-8118aab825bd --><!-- end item c7154ec2-e797-4197-8e37-c1740934066d -->","subChapters":[{"id":"c6fb519d-bb25-5496-9ce1-72e731b23071","slug":"basis-for-recommendation-f56","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field dfb055dc-78bd-4e57-a071-7e3cea71b189 --><h4>Basis for recommendation</h4><!-- end field dfb055dc-78bd-4e57-a071-7e3cea71b189 -->","summary":null,"htmlStringContent":"<!-- begin item f569e034-a059-4f5f-b9b0-8b1e5a7585cb --><!-- begin field e5ee987d-c764-479b-800f-26583949c1ff --><p>This information is taken from the manufacturers' Summaries of Product Characteristics for tamoxifen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>] and tibolone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2016</a>], and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Joint Formulary Committee, 2019</a>]. The information on cytochrome P450 2D6 inhibitors is also taken from the UK Medicines Information (UKMi) publication <em>Tamoxifen and SSRI and SNRI antidepressants - is there an interaction</em><strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">UKMi, 2018</a>].</p><!-- end field e5ee987d-c764-479b-800f-26583949c1ff --><!-- end item f569e034-a059-4f5f-b9b0-8b1e5a7585cb -->","subChapters":[]}]},{"id":"5cdeb0ad-882c-56c0-9607-6e2a3756d8cd","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field 0785978c-cfa2-4b3e-8756-41faf2d60a05 --><h3>What information and advice should I give to a woman taking tamoxifen?</h3><!-- end field 0785978c-cfa2-4b3e-8756-41faf2d60a05 -->","summary":null,"htmlStringContent":"<!-- begin item 1fabf6ab-2d57-41c4-9a85-287c7ad54b16 --><!-- begin field faea3693-be76-4abc-8cd8-88f7cfb5d3af --><ul><li><strong>Advise the woman:</strong><ul><li>To continue taking tamoxifen unless told otherwise by her specialist.</li><li>That there is a small risk of endometrial cancer and thromboembolic disease associated with tamoxifen treatment.<ul><li>She should seek prompt medical attention if she experiences abnormal vaginal bleeding or discharge, or symptoms of thromboembolism (such as pain and swelling in the calf of one leg, or sudden breathlessness).</li></ul></li><li>To seek medical attention if she experiences any other <a class=\"topic-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/management/tamoxifen-prescribing-information/#adverse-effects\">adverse effects</a> associated with tamoxifen treatment, such as gastrointestinal symptoms, visual problems, or skin disorders.</li><li>To discuss with her consultant if she is scheduled for elective surgery, due to the increased risk of thromboembolic events. <ul><li>For women taking tamoxifen for the primary prevention<em> </em>of breast cancer or for the treatment of anovulatory infertility, tamoxifen should be stopped at least 6 weeks before surgery or long-term immobility, and restarted only when the woman is fully mobile.</li><li>For women taking tamoxifen for the treatment of breast cancer, tamoxifen should not be stopped before surgery or long-term immobility unless the risk of tamoxifen-induced thrombosis clearly outweighs the risk of interrupting treatment.</li></ul></li></ul></li><li><strong>For a woman of childbearing potential, </strong>advise that she should not become pregnant whilst taking tamoxifen or within two months of cessation of tamoxifen treatment.<ul><li>Inform the woman on the potential risks to the foetus should she become pregnant whilst taking tamoxifen or within two months of cessation of tamoxifen treatment. </li><li>She should use barrier or other adequate non-hormonal contraceptive methods if sexually active.<strong> </strong>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for information on choosing a suitable method of contraception.</li><li>Advise that she should discuss with her consultant if she is trying to conceive. </li></ul></li><li><strong>For premenopausal women taking tamoxifen, </strong>advise that tamoxifen has been associated with reduced bone density.<ul><li>Advise on measures to maintain bone health. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a> for more information.</li></ul></li><li><strong>Ensure the woman is aware of the need for periodic monitoring for serious <a class=\"topic-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/management/tamoxifen-prescribing-information/#adverse-effects\">adverse effects</a> of tamoxifen. </strong><ul><li>This is usually done in secondary care and may include breast and gynaecological examination.</li></ul></li><li><strong>Provide written information on tamoxifen.</strong><ul><li>A patient information booklet on <a data-hyperlink-id=\"c21f0f3b-bd4c-4323-9597-ab1000a134c9\" href=\"https://breastcancernow.org/sites/default/files/publications/pdf/bcc20_tamoxifen_2018_web.pdf\">Tamoxifen</a> is available from <a data-hyperlink-id=\"3ebf86c6-7c9e-44b8-8397-ab1000a134f0\" href=\"https://breastcancernow.org/\">Breast Cancer Now</a>.</li></ul></li></ul><!-- end field faea3693-be76-4abc-8cd8-88f7cfb5d3af --><!-- end item 1fabf6ab-2d57-41c4-9a85-287c7ad54b16 -->","subChapters":[{"id":"2822e711-c5c9-515f-9bdc-f7d3f5e74dc4","slug":"basis-for-recommendation-181","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c5e20755-ae74-4a30-946b-541aa7723500 --><h4>Basis for recommendation</h4><!-- end field c5e20755-ae74-4a30-946b-541aa7723500 -->","summary":null,"htmlStringContent":"<!-- begin item 1813dfa3-c78f-4dc5-b2ee-bff798071303 --><!-- begin field c10475ef-ea9f-47cd-8e0a-ea89fea722c6 --><p>These recommendations are largely based on the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Joint Formulary Committee, 2019</a>].</p><h5>Bone mineral density</h5><ul><li>This recommendation is also based on the National Institute for Health and Care Excellence (NICE) guideline <em>Early and locally advanced breast cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">NICE, 2018</a>] and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Heery, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Ramchand, 2019</a>].<ul><li>Tamoxifen is a <a class=\"topic-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/background-information/definition/\">selective oestrogen receptor modulator</a> (SERM) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Heery, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Ramchand, 2019</a>].</li><li>In contrast to its action as a pure oestrogen receptor antagonist in breast tissue, tamoxifen acts as a partial oestrogen receptor agonist in bones and its actions depend on menopausal status (as tamoxifen is less potent than native oestradiol) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Ramchand, 2019</a>]:<ul><li>In premenopausal women, in whom circulating oestradiol concentrations are high, tamoxifen acts as a partial antagonist, competing with oestradiol for the oestrogen receptor-binding sites and causing bone loss. </li><li>In postmenopausal women, where endogenous oestradiol concentrations are low, tamoxifen acts as a partial agonist, preventing bone loss and reducing fracture risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Ramchand, 2019</a>].</li></ul></li><li>NICE states that the benefits and risks of tamoxifen treatment, including possible bone density loss in premenopausal women should be discussed with the woman [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">NICE, 2018</a>]. </li><li>The manufacturer states that the use of tamoxifen for reduction of breast cancer risk has been associated with reduced bone density in premenopausal women, and advises that premenopausal women taking tamoxifen for this reason should be advised regarding measures to maintain bone health [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">ABPI, 2018</a>]. </li></ul></li></ul><h5>Periodic specialist monitoring</h5><ul><li>This recommendation is based on an American drug database [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tamoxifen-managing-adverse-effects/references/\">Micromedex, 2014</a>].<ul><li>Periodic monitoring will ensure that the serious adverse effects of tamoxifen are detected promptly.</li></ul></li></ul><!-- end field c10475ef-ea9f-47cd-8e0a-ea89fea722c6 --><!-- end item 1813dfa3-c78f-4dc5-b2ee-bff798071303 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}